

Ocular Melanoma – Guidelines for Management

You might choose to have this document available as you discuss a post diagnosis surveillance plan with your oncologist.

A biopsy determines risk: low, intermediate, high risk of metastasis

Low risk [D3, D6, D8 or Castle class 1A with small tumor (D<10mm and Th<3 mm)]->MRI of the abdomen q 6 month, chest X-ray qY (or both qY) for 5 years; then once a year or every other year.

Intermediate risk [M3, D6, D8 or D3, 6 amp/8 amp or Castle class 1B]->MRI of the abdomen q 6 month, chest X-ray qY for 5 years; then annually.

High risk [M3 8qA or Castle class 2]->MRI of the abdomen q 3 month, CT of the chest q6M for 2 years; then MRI of the abdomen, q 6 month, CT of the chest qY for additional 3 years; then MRI of the abdomen and chest X-ray qY.

For MRI study, usage of Eovist contrast dye and diffusion weighted imaging are recommended (MRI with/without Eovist to include dynamic post-contrast sequences, delayed post-contrast sequences and diffusion weighted imaging). Eovist is called Preovist in Canada; ask for this contrast with your MRI. CT scan of the chest with contrast dye is preferable but not mandatory (without contrast is good for lung lesion). Blood tests include CBC with differential, complete metabolic panel and LDH.

NO PET scan unless CT or MRI shows a mass or multiple bone metastasis is suspected.

CT of the abdomen is not sensitive for small liver metastasis. Ultrasound of the abdomen could be ordered if MRI is not approved; however, sensitivity is much less, compared to MRI study.

Definitions:

D. Disomy

M. Monosomy

Castle refers to Castle Biosciences Decision UX testing (in Canada we can choose Impact Genetics testing)

3 6 8. Chromosomes

Tumour measurements - D diameter Th thickness

MRI magnetic resonance imaging - best choice for liver scan

Amp. Amplification

8qA. Amplification of chromosome 8q

q6 month. Every six months

qy. Every year

CT. Computed tomography scan

Scanning frequency recommended by Thomas Jefferson Hospital, Philadelphia - world leaders in treating ocular melanoma metastasis

Dec-2018